MARATTO

article · The Lancet Microbe

Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study

20246 citationsOpen accessUniversity of the Free State

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

AstraZeneca.

Research topics

  • SARS-CoV-2 and COVID-19 Research
  • Vaccine Coverage and Hesitancy
  • COVID-19 Clinical Research Studies

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher siteRecord on OpenAlex

DOI: 10.1016/s2666-5247(24)00078-8

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

Sign in to join the discussion

New to MARATTO™? Create a free account.